<DOC>
	<DOCNO>NCT00565474</DOCNO>
	<brief_summary>Principal objective investigate treatment fluvastatin prevent progression vascular graft disease de novo renal transplant patient .</brief_summary>
	<brief_title>Evaluation Effect Fluvastatin 40 mg ( b.i.d . ) Prevention Development Vasculopathy Graft de Novo Renal Transplant Patients Transplant</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Inclusion criterion : Patients investigator expect prescribe cyclosporine , mycophenolate mofetil corticosteroid base immunosuppressive therapy , regardless participation study . Man woman age 17 70 year . Patients receive first second renal transplant nonliving donor Patients allograft biopsy may perform . Patients receive identical compatible ABO graft . Patients willing give write informed consent study issue . Women childbearing potential use medically proven contraceptive method study . Patients able meet study requirement . Exclusion criterion : Patients pretransplant cholesterol level 240 mg/dl ( 6.2 mmol/l ) . Positive crossmatch T cell ABO incompatibility donor . Recipients multiorgan transplant . Patients diabetes mellitus . HIV seropositive surface antigen Hepatitis B . Kidney donor age 65 year . Last panel reactive antibody ( PRA ) 50 % . Women plan get pregnant within 12 month , pregnant and/or nursing . Patients history cancer previous 5 year , except patient successfully treat localized carcinoma squamous basal cell skin , cervix cancer situ treat adequately . Patients receive investigational drug 30 day prior transplant and/or receive investigational/nonregistered drug study , except use erythropoietinstimulating product Patients myocardial infarction within 6 month prior transplant , uncontrollable cardiac arrhythmia another severe unstable medical condition probably affect safety patient study objective . Patients alcohol dependence drug abuse solve , sign organic lesion cause alcohol , mental dysfunction factor limit ability fully cooperate study . Patients plan perform induction treatment preparation contain antilymphocyte antibody ( ALG , ATG OKT3 ) . Patients schedule receive cyclosporine i.v . 48 hour . Patients liver dysfunction ( ALT AST value total bilirubin 2 time upper limit normal range laboratory value ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>fluvastatin</keyword>
</DOC>